SNPHF Stock Financial Analysis - Santen Pharmaceutical Co., Ltd. (OTCPK) Stock

Overview

Santen Pharmaceutical Co., Ltd., based in Japan, is a renowned entity in the pharmaceutical industry, particularly recognized for its focus on ophthalmology. The company is dedicated to the development, production, and marketing of pharmaceutical products, over-the-counter drugs, and medical devices, primarily for eye care. Key projects encompass a broad range of therapies for ocular diseases, including glaucoma, dry eye, and retinal diseases. Santen's commitment to innovation is evident in its extensive R&D initiatives, aiming to bring forth advanced solutions for eye health worldwide. The company's strategic approach combines global expansion with a solid domestic presence, making it a significant player in the international pharmaceutical landscape.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 293,970.00 MM.
The operating income for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 43,699.00 MM.
The net income for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 31,501.00 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	293,970.00	43,699.00	31,501.00
2025-03-31	300,004.00	48,295.00	36,256.00
2024-12-31	301,905.00	51,223.00	27,494.00
2024-09-30	302,563.00	50,959.00	26,133.00
2024-06-30	304,347.00	52,591.00	26,861.00
2024-03-31	301,965.00	38,540.00	26,642.00
2023-12-31	302,084.00	81,605.00	27,729.00
2023-09-30	295,928.00	79,419.00	26,374.00
2023-06-30	285,893.00	39,716.00	-11,197.00
2023-03-31	279,037.00	35,300.00	-14,948.00
2022-12-31	270,242.00	-651.00	-8,195.00
2022-09-30	266,413.00	-1,951.00	-9,130.00
2022-06-30	266,804.00	35,053.00	26,539.00
2022-03-31	266,257.00	35,875.00	27,218.00
2021-12-31	263,620.00	52,619.00	5,062.00
2021-09-30	259,459.00	53,627.00	7,324.00
2021-06-30	257,028.00	54,648.00	7,983.00
2021-03-31	249,605.00	53,508.00	6,830.00
2020-12-31	241,015.00	38,185.00	24,434.00
2020-09-30	241,685.00	39,536.00	24,283.00
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	77.66	77.39
2024-09-30	73.26	73.03
2024-06-30	73.88	73.64
2024-03-31	72.62	72.37
2023-12-31	74.79	74.66
2023-09-30	69.65	69.58
2023-06-30	-29.38	-29.37
2023-03-31	-38.60	-38.60
2022-12-31	-20.85	-20.87
2022-09-30	-23.03	-23.04
2022-06-30	66.49	66.39
2022-03-31	68.07	67.97
2021-12-31	12.65	12.64
2021-09-30	18.32	18.29
2021-06-30	19.97	19.94
2021-03-31	17.09	17.06
2020-12-31	61.17	61.04
2020-09-30	60.80	60.66
2020-06-30	58.62	58.48
2020-03-31	59.16	59.01

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 56,509.00 MM.
The cash from investing activities for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is -9,399.00 MM.
The cash from financing activities for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is -49,713.00 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	56,509.00	-9,399.00	-49,713.00
2025-03-31	60,928.00	-8,223.00	-53,307.00
2024-12-31	55,247.00	-7,663.00	-55,157.00
2024-09-30	73,225.00	-6,839.00	-46,597.00
2024-06-30	82,244.00	-4,461.00	-39,206.00
2024-03-31	72,649.00	-6,145.00	-34,031.00
2023-12-31	68,107.00	-8,906.00	-40,546.00
2023-09-30	46,547.00	-11,750.00	-40,760.00
2023-06-30	37,272.00	-23,251.00	-37,209.00
2023-03-31	37,147.00	-26,777.00	-37,220.00
2022-12-31	43,335.00	-35,532.00	-18,289.00
2022-09-30	37,279.00	-36,923.00	-13,538.00
2022-06-30	45,922.00	-36,513.00	-2,042.00
2022-03-31	46,043.00	-35,169.00	5,557.00
2021-12-31	46,172.00	-26,281.00	-7,877.00
2021-09-30	47,476.00	-25,678.00	-6,942.00
2021-06-30	33,903.00	-47,673.00	-16,846.00
2021-03-31	38,808.00	-53,355.00	-16,685.00
2020-12-31	36,409.00	-51,958.00	-14,171.00
2020-09-30	34,787.00	-48,001.00	-13,538.00
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 0.08.
The roe for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 0.12.
The roic for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 0.11.
The croic for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is -0.00.
The ocroic for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 0.19.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.08	0.12	0.11	-0.00	0.19
2025-03-31	0.06	0.09	0.10	-0.01	0.20
2024-12-31	0.06	0.09	0.09	0.07	0.25
2024-09-30	0.06	0.09	0.09	0.14	0.27
2024-06-30		0.09
2024-03-31		0.09
2023-12-31			0.09	-0.01
2023-09-30			-0.04	-0.07
2023-06-30		-0.03
2023-03-31		-0.04
2022-12-31
2022-09-30		0.00
2022-06-30		0.00	0.00
2022-03-31		0.00	0.00
2021-12-31		0.00
2021-09-30	0.02	0.02
2021-06-30	0.02		0.02	-0.09	0.11
2021-03-31	0.02	0.02	0.02	-0.09	0.12
2020-12-31	0.06	0.08	0.08	-0.09	0.12
2020-09-30	0.06	0.08	0.07	-0.08	0.11
2020-06-30	0.06	0.08	0.07	0.05	0.13
2020-03-31	0.06	0.08	0.08	0.07	0.13

Gross Margins

The gross margin for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 0.57.
The net margin for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 0.12.
The operating margin for Santen Pharmaceutical Co., Ltd. as of June 30, 2025 is 0.16.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.57	0.12	0.16
2025-03-31	0.57	0.09	0.17
2024-12-31	0.58	0.09	0.17
2024-09-30	0.59	0.09	0.17
2024-06-30
2024-03-31
2023-12-31
2023-09-30		-0.04	0.14
2023-06-30		-0.04	0.14
2023-03-31		-0.05	-0.01
2022-12-31
2022-09-30		0.00	0.00
2022-06-30		0.00	0.00
2022-03-31
2021-12-31
2021-09-30
2021-06-30	0.61	0.03	0.21
2021-03-31	0.61	0.03	0.05
2020-12-31	0.60	0.10	0.16
2020-09-30	0.60	0.10	0.16
2020-06-30	0.60	0.10	0.16
2020-03-31	0.61	0.10	0.14

JP:4536	¥1,614.00
DE:SZD	€9.15